Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lumexa Imaging Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lumexa Imaging Holdings's regulatory disclosures and financial reporting.
Lumexa Imaging Holdings, Inc. reported preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025 and reiterated its full-year 2026 guidance. Full-year 2025 total revenues rose to $1,023,081 thousand from $948,869 thousand, while net loss narrowed to $47,104 thousand from $94,099 thousand. Adjusted EBITDA increased to $230,154 thousand from $200,839 thousand, reflecting stronger operating performance. Basic and diluted loss per share improved to $0.66 from $1.35. Outpatient volumes grew, with consolidated total procedures up 4.6% for 2025 and consolidated advanced procedures up 7.8%. The company strengthened its balance sheet: cash and cash equivalents increased to $58,828 thousand from $26,131 thousand, and long-term debt (less current maturities) declined to $819,029 thousand from $1,185,080 thousand, supported by initial public offering proceeds of $434,750 thousand.
Lumexa Imaging Holdings, Inc. released preliminary, unaudited fourth quarter and full year 2025 results and issued 2026 guidance. For 2025, GAAP net loss was $43,768 thousand, improving from $94,099 thousand in 2024, while Adjusted EBITDA rose to $229,029 thousand from $200,839 thousand. Fourth quarter 2025 Adjusted EBITDA was $62,625 thousand, up from $53,742 thousand a year earlier, with management citing expected Adjusted EBITDA growth of at least 14%. System-wide total procedures reached 3,972,228 in 2025, with advanced procedures growing and PET volumes up 17.0% on a consolidated basis and 13.5% system-wide. The company highlights expansion of de novo centers, one acquisition, new joint venture partnerships, and early adoption of AI-powered breast arterial calcification assessments as drivers of growth.
Lumexa Imaging Holdings, Inc. reported that its Principal Accounting Officer, Walker James Edward Jr., acquired 12,414 shares of common stock in the form of restricted stock units. The grant carried a price of $0.0000 per share, indicating it was an equity award rather than an open-market purchase.
Each RSU represents the contingent right to receive one share of Lumexa common stock. The RSUs vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, conditioned on Mr. Walker’s continued service with the company. Following this award, his directly owned common stock and RSUs total 17,346 shares.
Welsh, Carson, Anderson & Stowe entities report majority ownership of Lumexa Imaging Holdings, Inc. The reporting group, through Lumexa Imaging Holdings, LLC, beneficially owns 70,217,616 shares of Lumexa common stock, representing 74.3% of the company’s outstanding shares.
These percentages are based on 94,565,652 shares of common stock outstanding after Lumexa’s initial public offering, as stated in the company’s final prospectus. The ownership is shared among Welsh, Carson, Anderson & Stowe XII, L.P., WCAS XII Associates LLC, and WCAS Management Corporation, reflecting their control and investment advisory roles.
After a 180-day lock-up period following the December 12, 2025 IPO closing, Lumexa Imaging Holdings, LLC may distribute its shares to equity holders on a pro rata basis. Up to 28,595,386 shares could be received by various Welsh, Carson, Anderson & Stowe affiliates in a full distribution, while remaining shares would go to unaffiliated holders, reducing the group’s shared beneficial ownership.
Lumexa Imaging Holdings, Inc. reported that its Chief Financial Officer, Martin James Anthony, received two grants of common-stock-based compensation on December 12, 2025. Each grant covers 27,027 restricted stock units (RSUs) at a price of $0 per share, for a total of 54,054 RSUs now beneficially owned directly.
One RSU grant vests in three roughly equal annual installments on each of the first three anniversaries of the grant date, as long as he remains with the company. The second grant vests in three equal parts if the stock reaches volume-weighted average price targets of $27.00, $36.00 and $45.00 over any 60‑trading‑day period within up to four years, also subject to continued service.
Lumexa Imaging Holdings, Inc. reported initial equity holdings for Chief Financial Officer Martin James Anthony. He beneficially holds two stock option awards, each covering 388,888 shares of common stock at an exercise price of $18.50 per share. One option vests in five substantially equal annual installments starting from January 1, 2025, conditioned on his continued service. The second option vests in three installments tied to stock price targets of $27.00, $36.00, and $45.00 per share, measured over any 60‑trading‑day volume weighted average price after a 180‑day lock‑up period, also requiring continued service. The filing notes it was submitted late due to delays obtaining EDGAR codes.
Lumexa Imaging Holdings, Inc. reported that its Chief Legal Officer and Corporate Secretary, Julie Szeker, submitted her resignation effective March 13, 2026. The company stated that her resignation is not due to any disagreement over operations, policies or practices and has begun a search for a successor.
Under a transition letter agreement, Ms. Szeker will receive a $450,000 transition payment and up to 12 months of subsidized healthcare coverage, subject to a release of claims and compliance with the agreement. She will also receive an annual bonus of $250,000 related to 2025 performance, payable at the same time as bonuses to other employees.
Lumexa Imaging Holdings, Inc. disclosed that its subsidiaries entered into an amended credit agreement led by Barclays Bank PLC. The agreement provides a secured term loan facility of $825 million maturing in December 2032 and a secured revolving credit facility of $250 million maturing in December 2030. Both facilities bear interest at the borrowers’ option at SOFR plus 3.00% or the Prime Rate plus 2.00%, with potential rate reductions on the revolver if certain senior secured net leverage ratios are met. The facilities are guaranteed by substantially all wholly owned subsidiaries and secured by substantially all of their assets, and include restrictive covenants and a financial covenant requiring a consolidated net leverage ratio not exceeding 7.50 to 1 if revolving borrowings exceed 40% of the revolver commitment at a quarter-end.
Lumexa Imaging Holdings, Inc. director filed an initial ownership report detailing derivative interests tied to the company’s common stock. The filing shows rights to receive 64,379 shares of common stock through Common Units of Lumexa Imaging Equity Holdco, LLC held directly, and an additional 91,256 shares indirectly through Charlotte Radiology Investors, LLC. Each nine Common Units correspond to one share of Lumexa Imaging’s common stock held by the LLC. After the IPO, Lumexa Imaging Equity Holdco, LLC may distribute its common shares to equity holders on a pro rata basis, but not before a 180-day lock-up period expires, and the director’s reported interests relate to shares that could be received in such a distribution.
Lumexa Imaging Holdings, Inc. reported that its Chief Executive Officer and director received two equity awards on December 12, 2025 totaling 129,728 restricted stock units (RSUs), each RSU representing one share of common stock. Each grant covers 64,864 RSUs at an acquisition price of $0 per share.
The first 64,864 RSUs vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the executive’s continued service. The second 64,864 RSUs vest in three substantially equal installments upon achieving stock price targets of $27.00, $36.00 and $45.00 per share, based on 60‑trading‑day volume weighted average prices over measurement periods that can extend to the fourth anniversary of the grant, also requiring continued service.